Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.

Bauer G, Dao MA, Case SS, Meyerrose T, Wirthlin L, Zhou P, Wang X, Herrbrich P, Arevalo J, Csik S, Skelton DC, Walker J, Pepper K, Kohn DB, Nolta JA.

Mol Ther. 2008 Jul;16(7):1308-15. doi: 10.1038/mt.2008.93. Epub 2008 May 6.

2.

Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy.

Lalani AS, Chang B, Lin J, Case SS, Luan B, Wu-Prior WW, VanRoey M, Jooss K.

Mol Ther. 2004 Jan;9(1):56-66.

3.

Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cells.

Price MA, Case SS, Carbonaro DA, Yu XJ, Petersen D, Sabo KM, Curran MA, Engel BC, Margarian H, Abkowitz JL, Nolan GP, Kohn DB, Crooks GM.

Mol Ther. 2002 Nov;6(5):645-52.

4.

Lentiviral vector gene transfer into fetal rhesus monkeys (Macaca mulatta): lung-targeting approaches.

Tarantal AF, Lee CI, Ekert JE, McDonald R, Kohn DB, Plopper CG, Case SS, Bunnell BA.

Mol Ther. 2001 Dec;4(6):614-21.

5.

Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems.

Tarantal AF, O'Rourke JP, Case SS, Newbound GC, Li J, Lee CI, Baskin CR, Kohn DB, Bunnell BA.

Mol Ther. 2001 Feb;3(2):128-38.

6.
7.
8.

Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors.

Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2988-93.

9.

Gene delivery to human B-precursor acute lymphoblastic leukemia cells.

Mascarenhas L, Stripecke R, Case SS, Xu D, Weinberg KI, Kohn DB.

Blood. 1998 Nov 15;92(10):3537-45.

PMID:
9808545
10.

Supplemental Content

Support Center